Skip to main content
. 2023 Jul 24;45(1):2237124. doi: 10.1080/0886022X.2023.2237124

Figure 4.

Figure 4.

Kaplan–Meier curves for the complete remission after Rituximab in patients with MN and podocytopathy. Kaplan–Meier curves were shown for the proportion of cumulative complete remission during the follow-up period in patients receiving Rituximab with membranous nephropathy (MN) compared with the patients in podocytopathy group. 95% CI: 95% confidence interval; HR: hazard ratio. p < 0.05 was considered to be statistically significant.